Latest Content

Abstracts presented at ASH 2025 explore CAR T-cell therapy's effectiveness in newly authorized treatment centers, revealing promising outcomes for multiple myeloma patients and the prospect of expanded access.

In an interview during ASH 2025, Ontada's Ira Zackson, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia treatment, highlighting real-world challenges and emerging therapy strategies.

Dani Castillo, MD, sheds light on the evolving landscape of first-line therapy in advanced gastric cancer.

W. Kimryn Rathmell, MD, PhD, FASCO, champions the dyad model to enhance oncology care accessibility, bridging gaps between rural patients and clinical trials.

The Chief Medical Officer of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and safety in non-Hodgkin lymphoma treatment. This exchange appears in the January issue of Evidence-Based Oncology, the annual recap of the meeting of the American Society of Hematology.

The complex disparities in pancreatic cancer survival trends across demographics and regions highlight urgent needs for targeted interventions.

Filippo Pietrantonio, MD, discusses findings from the phase 1/2 OrigAMI-1 study in RAS/BRAF wild-type mCRC.

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant breakthrough in treatment options.

Reduced doses and shorter durations of venetoclax can enhance treatment outcomes and reduce adverse events in acute myeloid leukemia (AML).